Acacia Files Additional Patent Infringement Lawsuits against Cable TV Companies; Lawsuits Follow Recent Licensing of 4 Cable Companies.NEWPORT BEACH, Calif. -- Acacia Research Corporation (Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator )(Nasdaq:CBMX) announced today that its Acacia Media Technologies Corporation subsidiary has initiated patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. against cable companies located in Arizona, Minnesota, and Ohio, for infringement of Acacia's DMT See DSL. (R) Patents. The Company previously initiated patent infringement litigation in June of this year against 6 cable companies in the Northern District of California, 3 of which have settled and signed licensing agreements. Companies named in the lawsuits include Armstrong Group, Arvig Communication Systems, Block Communications, Inc., Cable America Corporation, Cable One, Inc., Cable System Services, Inc., Cannon Valley Communications, Inc., East Cleveland Cable TV and Communications, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , Loretel Cablevision, Massillon Cable TV, Inc., Mid-Continent Media, Inc., Nelsonville TV Cable, Inc., NPG NPG Nature Publishing Group (Macmillan Publishers, Ltd) NPG National Portrait Gallery (UK) NPG NIOSH Pocket Guide to Chemical Hazards NPG New Power Generation (Prince) Cable, Inc., Precis Communications, Inc., San Carlos Cablevision, LLC, Savage Communications, Inc., Sjoberg's Cablevision, Inc., US Cable, and Wide Open West, LLC. The Company also announced today that it added Mediacom LLC to its Northern California litigation. Paul Ryan, Chairman and Chief Executive Officer commented, "We continue to make great progress with our DMT(R) licensing program. Of our 175 licensing agreements, 140 licenses were signed without the need for litigation and 35 were signed after litigation was initiated. Although we have recently licensed four cable TV companies and are making progress in licensing discussions with several other cable companies, it may be necessary to bring lawsuits from time to time to enforce our intellectual property." Rob Berman, Executive Vice President and General Counsel stated, "Litigation is often a necessary part of the licensing business. Experience has shown us that litigation is required before some companies enter into serious licensing discussions. Although litigation is not our preferred course of action, we are prepared to see these cases through to trial if necessary." Acacia has entered into 175 license agreements for its DMT(R) technology for cable TV, corporate websites, e-learning, hotel on-demand TV services, and online entertainment, movies, music, news, and sports. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group. The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia's DMT(R) technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems. Acacia's Internet Access Redirection ("IAR IAR - Instruction Address Register. The IBM name for program counter. ") technology covers redirected Internet registrations commonly used at wireless hotspots and hotels. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics, drug discovery, and immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. CombiMatrix's Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion